表紙
市場調查報告書

Gorlin症候群(基底細胞母斑症候群):開發中產品分析

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 465217
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
Gorlin症候群(基底細胞母斑症候群):開發中產品分析 Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019
出版日期: 2019年11月29日內容資訊: 英文 148 Pages
簡介

所謂Gorlin症候群(基底細胞母斑症候群),影響身體各種部位,提高發展為各種癌症性及非癌症性腫瘤的風險。症狀有心律不整,髓芽細胞腫,卵巢線維腫、 皮膚的陷凹,前頂突出及脊椎、肋骨、顱骨等骨骼異常等。治療手術為放射治療,化療等。

本報告提供Gorlin症候群(基底細胞母斑症候群)的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

Gorlin症候群(基底細胞母斑症候群);概要

治療藥的開發

  • 開發中產品;概要
  • 各企業開發中產品
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adgero Biopharmaceuticals Holdings Inc
  • Galderma SA
  • Mayne Pharma Group Ltd
  • PellePharm Inc
  • Transgene SA

藥物簡介

  • itraconazole
  • patidegib hydrochloride
  • REM-001
  • TG-1042
  • trifarotene

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11846IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline landscape.

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 1, 3, 1 and 2 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Overview
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Companies Involved in Therapeutics Development
    • Adgero Biopharmaceuticals Holdings Inc
    • Feldan Therapeutics Inc
    • Galderma SA
    • Genentech Inc
    • Mayne Pharma Group Ltd
    • Ono Pharmaceutical Co Ltd
    • PellePharm Inc
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drug Profiles
    • FTX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patidegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rostaporfin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trifarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome
      • Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS
      • Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs
      • Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference
      • Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA
      • Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
      • May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting
      • Feb 22, 2018: Adgero Biopharmaceuticals Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome
      • Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency
      • Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome
      • Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
      • Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas
      • Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission
      • May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
      • Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals' REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Feldan Therapeutics Inc, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Galderma SA, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Genentech Inc, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Mayne Pharma Group Ltd, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by PellePharm Inc, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects, H2 2019
  • Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top